Candida due to *Candida guilliermondii* in an immunocompromised infant: a case report and review of literature

Fatemeh Ahangarkani¹, ², Hamid Badali³, Mohammad Sadegh Rezai³, Tahereh Shokohi², Zahra Abtahian⁴, Hassan Mahmoodi Nesheli⁵, Hossein Karami⁵, Emmanuel Roilides⁷, Ahmad Tamaddoni⁵*

¹ Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran
² Invasive Fungi Research Center/Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
³ Infectious Diseases and Tropical Medicine Research Center, Mazandaran University of Medical Sciences, Sari, Iran
⁴ Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
⁵ Amirkola Children Hospital, Babol University of Medical Sciences, Babol, Iran
⁶ Thalassemia Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran
⁷ 3rd Department of Pediatrics, Infectious Diseases Section, Faculty of Medicine, Aristotle University School of Health Sciences, Thessaloniki, Greece

**Article Info**

**Article type:** Case report

**Article History:**
Received: 02 November 2018
Revised: 25 December 2018
Accepted: 27 January 2019

**Corresponding author:**
Ahmad Tamaddoni
Amirkola Children Hospital, Babol University of Medical Sciences, Babol, Iran.
Email: drtamaddoni@yahoo.com

**Background and Purpose:** Candidemia is a life-threatening fungal infection with significant mortality and morbidity in neutropenic individuals, immunosuppressive chemotherapy recipients, and broad-spectrum antibiotics consumers. The epidemiology and antifungal susceptibility testing of non-∗albicans Candida* species have been poorly studied. These species are characterized by low susceptibility to azoles and echinocandins. Herein, we report the first pediatric case of candidemia due to *C. guilliermondii* in Iran and review the literature on fungemia caused by *C. guilliermondii*.

**Case report:** We presented the first candidemia case due to *C. guilliermondii* in a 4-month-old male infant with neuroblastoma in Iran. This study also involves a comprehensive literature review on fungemia caused by *C. guilliermondii* during a period of 18 years (i.e., 2000-2018) to discuss the epidemiology, clinical features, and treatment of this disease. The literature review resulted in the identification of 501 cases of candidemia caused by *C. guilliermondii*. Most of the patients were adults and had multiple risk factors. However, the main risk factors were significantly related to cancer chemotherapy, followed by central venous catheter use and Intensive Care Unit admission. Mortality rate due to this disease had a range of 3.4-66.6%, in this regard, the patients with cancer had the highest mortality rate.

**Conclusion:** Given the high mortality of candidemia, the early diagnosis of this infection and timely initiation of antifungal therapy significantly improve the patients’ survival rate and result in better outcomes. Consequently, it is highly recommended to monitor the local epidemiology of this life-threatening infection and raise awareness in this regard.

**Keywords:** *Candida guilliermondii*, Candidemia, Cancer, Pediatric

---

**Introduction**

Candidemia is a life-threatening fungal infection with significant morbidity and mortality among pediatric patients, especially among those subjected to intravenous catheters for a long time, hematopoietic stem cell transplantation, and immunosuppressive therapy or the patients with severe immunodeficiency and cancer [1]. Although *Candida albicans* is generally the most frequent cause of candidemia, non-∗albicans Candida* species (i.e., *C. glabrata*, *C. tropicalis*, *C. krusei*, *C. parapsilosis*, *C. auris*, and *C. guilliermondii*) have become more frequent and have been recognized as emerging pathogens in cancer patients [1, 2].

Accordingly, the incidence rate of candidemia due to *C. guilliermondii* ranges from 0.6% in North America to 3.7% in Latin America. In addition, the decreased susceptibility of this pathogenic yeast to fluconazole has been observed in different geographical areas [1-4]. However, the epidemiology of candidemia due to *C. guilliermondii* has been underestimated so far. Herein, we report the first pediatric case of candidemia due to *C. guilliermondii*...
in Iran and present a comprehensive literature review regarding fungemia caused by *C. guilliermondii*.

**Case report**

Our case was a 4-month-old male infant with neuroblastoma undergoing chemotherapy referred to the Oncology Department of Amirkola Children’s Hospital, Mazandaran, Iran, with fever and neutropenia, without any obvious source of infection. The patient had undergone surgery for neuroblastoma 2 months prior. Laboratory examinations showed the C-reactive protein level of 76 mg/L, white blood cell count of 1.8×10⁹/µL (i.e., leukopenia), neutrophil count of <500 cell/µL, hemoglobin level of 6.5 g/dL, and platelet count of 134×10⁹/µL. The blood samples were collected aseptically by arterial puncture in BD BACTEC Plus Aerobic/F culture bottles (Becton Dickinson and Company Spark, MD 21152, Shannon, County Clare, Ireland) and incubated in a BACTEC culture system (Becton Dickinson Microbiology Systems).

The patient was prescribed ciprofloxacin prophylaxis due to mucositis; in addition, empirical therapy with ceftazidime and vancomycin was instituted for up to 7 days; however, his condition deteriorated rapidly. Initial blood cultures were negative for bacteria, whereas two consecutive blood cultures were positive for yeast-like fungi. Positive blood cultures were subcultured on CHROMagar *Candida* (bioMe rieux) and resulted in the emergence of smooth colonies with white to cream colors after 24 h in dark. *Candida* species were initially identified based on conventional assays.

Voucher strains were deposited into the reference culture collection under the accession number IFRC2085. In addition, identification at the species level was performed by using DNA sequencing. Genomic DNA was extracted from 2 to 3-day-old Sabouraud dextrose agar cultures with an UltraClean Microbial DNA Isolation Kit (Mo Bio Laboratories) according to the manufacturer’s protocol, and then stored at -20°C prior to use. The internal transcribed spacer (ITS) was amplified and sequenced using primers ITS5 and ITS4 as previously described [5].

Briefly, the amplification of ITS rDNA was performed using a cycle of 5 min at 94°C for primary denaturation, followed by 40 cycles at 94°C for 30 sec, 52°C for 30 sec, and 72°C for 80 sec and a final 7-min extension step at 72°C. The sequence data were adjusted using Lasergene SeqMan software (version 9.0.4, DNASTAR) and compared with the data of GenBank through local BLAST with a molecular database maintained for research purposes at the CBS-KNAW Fungal Biodiversity Centre, Utrecht, Netherlands. The DNA sequence of the ITS rDNA region matched that of *C. guilliermondii* (MH714912) by showing 99.9% similarity with the ex-type strain.

In vitro antifungal susceptibility test was also performed according to the documents M27-A3 and M27-S4 of the Clinical and Laboratories Standards Institute. For the preparation of the microdilution trays, amphotericin B (Sigma, St. Louis, MO, USA), fluconazole (Pfizer, Groton, CT, USA), itraconazole (Janssen research foundation, Beerse, Belgium), voriconazole (Pfizer), and caspofungin (Merck, Whitehouse Station, NJ, USA) were obtained from their respective manufacturers as reagent-grade powders. The minimum inhibitory concentrations for amphotericin B, fluconazole, itraconazole, voriconazole, and caspofungin were obtained as 0.063, 4, 0.25, and 0.5 µg/ml, respectively.

The patient was empirically treated with 0.75 mg/kg/day amphotericin B deoxycholate intravenously, which is a regimen frequently used as standard therapy for candidaemia in Iran. After treatment with amphotericin B for a week, two sequential blood cultures remained negative. The patient was successfully treated and showed no relapse during the two-week follow-up. This report was approved by the Ethics Committee of Mazandaran University of Medical Sciences, Mazandaran, Iran. In line with the principles of research ethics, written informed consent was obtained from the parents of the patient.

**Discussion**

*Candida guilliermondii* complex comprising several species, namely *C. guilliermondii*, *C. fermentati*, *C. carpophila*, and *C. xestobii*, is an uncommon, newly emerging, and rare agent of candidemia, with low incidence (1-3%), especially in immunocompromised hosts, transplant recipients, and critically ill patients [3].

Limited cases of invasive candidiasis caused by *C. guilliermondii* complex have been reported in the past because of its low pathogenicity. However, recently, there is an increasing number of reports regarding the bloodstream infections due to this complex [4]. In addition, due to resistance or decreased susceptibility to antifungal agents, *C. guilliermondii* complex has been proposed to be a re-emerging pathogen in high-risk patients.

Table 1 summarizes all reported cases of candidemia due to *C. guilliermondii* in English literature with the patients’ demographic characteristics (e.g., age, gender, source, and location) and clinical data (e.g., underlying condition, risk factors, and outcomes). Most of these patients were adults and had multiple risk factors. The main risk factors were significantly related to cancer patients undergoing chemotherapy, followed by central venous catheter users and ICU patients (Table 1). In the reviewed articles, the mortality rate had a range of 3.4-66.6%. In this regard, this infection had the mortality rates of 11.76-66.6%, 13.6-54%, 16.6-18.8%, 59.25%, and 3.4% in Japan, Spain, Taiwan, United States, and Italy, respectively (Table 1).

Cancer patients suffering from this infection had a high rate of mortality. While the majority of *C. guilliermondii* fungemia cases have been described in adults with cancer, few cases have been published in pediatric patients. Peman et al. reported seven cases of *C. guilliermondii* fungemia during a 12-year period,
<table>
<thead>
<tr>
<th>Number</th>
<th>Year of evaluation</th>
<th>Country</th>
<th>Underlying condition and predisposing factors</th>
<th>Pediatric/ adult</th>
<th>Number 1/total</th>
<th>Resistant to azoles</th>
<th>Resistant to echinocandins</th>
<th>Mortality rate</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>2018</td>
<td>Iran</td>
<td>- Cancer&lt;br&gt;- Chemotherapy&lt;br&gt;- Surgery&lt;br&gt;- Neutropenia&lt;br&gt;- 4-month-old infant</td>
<td>Adult</td>
<td>1/121</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>Current case</td>
</tr>
<tr>
<td>2.</td>
<td>2007-2016</td>
<td>Japan</td>
<td>- Hematological disorder&lt;br&gt;- Surgery&lt;br&gt;- ICU exposure</td>
<td>Adult</td>
<td>17/121</td>
<td>17.6-13.3%</td>
<td>0.00</td>
<td>11.76%</td>
<td>[1]</td>
</tr>
<tr>
<td>3.</td>
<td>2008-2014</td>
<td>Japan</td>
<td>- Hematopoietic stem cell transplant recipients</td>
<td>Adult</td>
<td>3/22</td>
<td>NS</td>
<td>NS</td>
<td>66.6%</td>
<td>[8]</td>
</tr>
<tr>
<td>4.</td>
<td>2006-2015</td>
<td>Turkey</td>
<td>- Cancer&lt;br&gt;- TPN&lt;br&gt;- CVC&lt;br&gt;- ICU exposure&lt;br&gt;- Chemotherapy</td>
<td>Both</td>
<td>141/NS</td>
<td>26.08%</td>
<td>NS</td>
<td>NS</td>
<td>[2]</td>
</tr>
<tr>
<td>5.</td>
<td>2007-2014</td>
<td>Spain</td>
<td>- Cancer&lt;br&gt;- Immunosuppressive therapy&lt;br&gt;- Neutropenia&lt;br&gt;- Chemotherapy</td>
<td>Both</td>
<td>22/NS</td>
<td>72%</td>
<td>0.00</td>
<td>13.6%</td>
<td>[4]</td>
</tr>
<tr>
<td>6.</td>
<td>2005-2014</td>
<td>USA</td>
<td>- Cancer&lt;br&gt;- ICU exposure&lt;br&gt;- Exposure to steroids</td>
<td>Pediatric</td>
<td>3/192</td>
<td>NS</td>
<td>NS</td>
<td>0.00</td>
<td>[9]</td>
</tr>
<tr>
<td>7.</td>
<td>2006-2012</td>
<td>Italy</td>
<td>- Cancer</td>
<td>Pediatric</td>
<td>1/28</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>[10]</td>
</tr>
<tr>
<td>8.</td>
<td>2003-2015</td>
<td>Taiwan</td>
<td>- Cancer&lt;br&gt;- CVC</td>
<td>Both</td>
<td>36/8</td>
<td>0.00</td>
<td>4.5-22.7%</td>
<td>16.66%</td>
<td>[11]</td>
</tr>
<tr>
<td>9.</td>
<td>2007-2014</td>
<td>Taiwan</td>
<td>- Cancer&lt;br&gt;- Neutropenia&lt;br&gt;- TPN&lt;br&gt;- Steroid exposure</td>
<td>Adult</td>
<td>11/21</td>
<td>81%</td>
<td>36%</td>
<td>18.18</td>
<td>[12]</td>
</tr>
<tr>
<td>10.</td>
<td>1998-2013</td>
<td>USA</td>
<td>- Cancer&lt;br&gt;- Neutropenia&lt;br&gt;- TPN&lt;br&gt;- Steroid exposure</td>
<td>Adult</td>
<td>28/790</td>
<td>17.24%</td>
<td>3.7%</td>
<td>59.25%</td>
<td>[7]</td>
</tr>
<tr>
<td>11.</td>
<td>2002-2007</td>
<td>Brazil</td>
<td>- Hematological disorder</td>
<td>Both</td>
<td>6/67</td>
<td>0.00</td>
<td>NS</td>
<td>NS</td>
<td>[13]</td>
</tr>
<tr>
<td>12.</td>
<td>March-April 2012</td>
<td>Spain</td>
<td>- TPN&lt;br&gt;- Steroid exposure&lt;br&gt;- CVC&lt;br&gt;- Surgery&lt;br&gt;- Broad-spectrum antibiotic exposure</td>
<td>Adult</td>
<td>4/13</td>
<td>0.00</td>
<td>54%</td>
<td>[14]</td>
<td></td>
</tr>
<tr>
<td>13.</td>
<td>2007-2013</td>
<td>Japan</td>
<td>- Cancer&lt;br&gt;- Chemotherapy&lt;br&gt;- CVC&lt;br&gt;- TPN&lt;br&gt;- Neutropenia&lt;br&gt;- Immunosuppressive therapy&lt;br&gt;- ICU exposure</td>
<td>Both</td>
<td>16/66</td>
<td>12.5%</td>
<td>6.2%</td>
<td>18.75%</td>
<td>[15]</td>
</tr>
<tr>
<td>14.</td>
<td>2009-2012</td>
<td>Taiwan</td>
<td>- Elderly patients&lt;br&gt;- Cancer&lt;br&gt;- Chemotherapy</td>
<td>Adult</td>
<td>2/181</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>[16]</td>
</tr>
<tr>
<td>15.</td>
<td>2009-2012</td>
<td>Taiwan</td>
<td>- Cancer&lt;br&gt;- CVC&lt;br&gt;- Neutropenia&lt;br&gt;- Use of steroid&lt;br&gt;- Recent abdominal surgery&lt;br&gt;- Chemotherapy&lt;br&gt;- TPN&lt;br&gt;- Broad-spectrum antibiotic exposure</td>
<td>Adult</td>
<td>2/209</td>
<td>NS</td>
<td>50%</td>
<td>NS</td>
<td>[17]</td>
</tr>
<tr>
<td>16.</td>
<td>2010-2011</td>
<td>Spain</td>
<td>- NS</td>
<td>NS</td>
<td>13/781</td>
<td>0</td>
<td>0</td>
<td>NS</td>
<td>[18]</td>
</tr>
<tr>
<td>17.</td>
<td>2007-2013</td>
<td>Spain</td>
<td>- Cancer</td>
<td>NS</td>
<td>7/593</td>
<td>42.85%</td>
<td>0</td>
<td>NS</td>
<td>[19]</td>
</tr>
<tr>
<td>18.</td>
<td>2009-2012</td>
<td>India</td>
<td>- Patients with injuries</td>
<td>NS</td>
<td>4/212</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>[20]</td>
</tr>
<tr>
<td>19.</td>
<td>2007-2010</td>
<td>Brazil</td>
<td>- NS</td>
<td>Pediatric</td>
<td>5/104</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>[21]</td>
</tr>
<tr>
<td>20.</td>
<td>2004-2008</td>
<td>USA</td>
<td>- Cancer&lt;br&gt;- Stem cell transplantation&lt;br&gt;- Chemotherapy</td>
<td>Both</td>
<td>9/2496</td>
<td>0</td>
<td>0</td>
<td>NS</td>
<td>[22]</td>
</tr>
<tr>
<td>21.</td>
<td>2009-2011</td>
<td>China</td>
<td>- Cancer&lt;br&gt;- CVC&lt;br&gt;- Preterm infants with low birth weight</td>
<td>Both</td>
<td>39/238</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>[23]</td>
</tr>
<tr>
<td>22.</td>
<td>2009-2010</td>
<td>France</td>
<td>- Cancer&lt;br&gt;- Preterm infants with low birth weight&lt;br&gt;- Immunosuppressive drugs user&lt;br&gt;- CVC</td>
<td>Both</td>
<td>1/189</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>[24]</td>
</tr>
<tr>
<td>23.</td>
<td>2004-2006</td>
<td>Taiwan</td>
<td>- NS</td>
<td>Both</td>
<td>6/152</td>
<td>NS</td>
<td>0</td>
<td>NS</td>
<td>[25]</td>
</tr>
<tr>
<td>24.</td>
<td>2006-2007</td>
<td>Brazil</td>
<td>- Cancer</td>
<td>Pediatric</td>
<td>9/20</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>[26]</td>
</tr>
<tr>
<td>25.</td>
<td>1995 to 2006</td>
<td>Spain</td>
<td>- Cancer&lt;br&gt;- CVC&lt;br&gt;- Chemotherapy&lt;br&gt;- ICU stay</td>
<td>Both</td>
<td>7/NS</td>
<td>42.85%</td>
<td>0</td>
<td>28.57%</td>
<td>[3]</td>
</tr>
<tr>
<td>26.</td>
<td>2003-2004</td>
<td>Brazil</td>
<td>- NS</td>
<td>Pediatric</td>
<td>6/149</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>[27]</td>
</tr>
<tr>
<td>27.</td>
<td>2001-2006</td>
<td>Ireland</td>
<td>- NS</td>
<td>Both</td>
<td>4/151</td>
<td>25-75%</td>
<td>NS</td>
<td>NS</td>
<td>[28]</td>
</tr>
</tbody>
</table>
five cases of which occurred in children [3]. In contrast, in a meta-analysis on the epidemiology of candidemia in Iran, C. guilliermondii accounted for 2 (3.8%) cases of infection in adults [6].

Our patient was an infant and had a history of chemotherapy and surgery. The epidemiology and antifungal susceptibility testing of C. guilliermondii complex have been poorly studied. This complex is characterized by low susceptibility to azoles and echinocandins. In line with our study demonstrating the susceptibility of C. guilliermondii to amphotericin B and its resistance to fluconazole, numerous studies have demonstrated high MICs for azoles [3-10]. Our literature review showed that the rates of high MICs for azoles and echinocandins were 0-81% and 0-50%, respectively. Although echinocandins therapy is highly effective, emerging drug resistance is a growing threat to successful clinical management.

Conclusion
This is the first report describing candidemia due to C. guilliermondii in a pediatric patient in Iran. Given the high mortality rate of this infection, the early diagnosis and initiation of appropriate antifungal therapy for this infection significantly improve the patients’ survival rate and result in better outcomes. It is highly recommended to monitor the local epidemiology of this life-threatening infection and obtain awareness in this regard.

Acknowledgments
The authors thank the staff of Amir Kola Children’s Hospital, Babol, Iran, for their cooperation, and are indebted to Ms. Movaghar for sampling and technical assistance.

Author’s contribution
F. A., H. B., MS. R., and A. T. contributed to study concept and managed the project; in addition, F. A., H. B., E. R., and A. T. wrote the first draft of the manuscript. Furthermore, F. A., H.B., MS. R., A. T., T. S., H. M. CH, E. R., and H. K. provided practical support and performed the critical revision of the manuscript.

Conflicts of interest
The authors have declared no conflicts of interest.

Financial disclosure
This study was financially supported by the National Institutes for Medical Research Development (NIMAD), Grant/Award Number (942173), Mazandaran University of Medical Sciences (grants No. 1262), Sari, Iran.

References
Candidemia due to Candida guilliermondii

Ahangarkani F et al.


